High-Throughput CTL Epitope Identification via T Cell Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying cytotoxic T cell (CTL) epitopes are inefficient, limiting the development of effective cancer immunotherapy and Hepatitis C Virus (HCV) vaccines, as they struggle to detect functional epitopes among the vast number of peptide-MHC class I complexes on cell surfaces, with most tumor-associated antigens being self-proteins that are tolerated by the immune system.
Innovation Solution
A high-throughput method involving the expression of candidate antigens and HLA molecules in antigen-presenting cells, using affinity-based algorithms to predict peptide binding, generating synthetic peptide:HLA complexes, and contacting T cells to induce responses, allowing for the identification of reactive T cells through cytokine production, upregulation of markers, or degranulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If mass spectrometry is used to identify MHC-bound peptides, then the entire MHC peptide repertoire can be described, but the sensitivity and functional relevance of identified epitopes remain insufficient
Solution Approach 1:
The patent introduces T cell responses as an intermediary to bridge the gap between peptide-MHC complexes and functional epitopes. By using T cell activation, cytokine production, and T cell receptor signaling as mediators, the method filters the vast number of predicted peptide-MHC complexes to identify only those that truly elicit immunological responses, thereby improving both sensitivity and reliability of epitope identification.
Solution Approach 2:
The patent implements feedback mechanisms where T cell responses provide information about the functional relevance of peptide-MHC complexes. The system uses T cell activation status, cytokine secretion levels, and T cell receptor engagement as feedback signals to validate predicted epitopes, creating an iterative process that refines epitope identification based on actual immunological responses.
2Adaptability or versatility
If T cells are used to detect self-peptides presented on self-HLA, then tumor-associated antigens can be identified, but tolerance deletes T cells that recognize self-peptides with high affinity
Solution Approach 1:
The patent applies preliminary action by using allogeneic or autologous T cells in a controlled in vitro setting before potential therapeutic application. The method pre-identifies and characterizes epitopes using T cells from donors with appropriate HLA types, allowing systematic study of self-peptide recognition without the constraints of in vivo tolerance. This preliminary characterization enables subsequent therapeutic use where tolerance issues can be managed through targeted approaches.
Solution Approach 2:
The patent applies local quality by focusing T cell recognition on specific peptide-MHC complexes rather than general self-peptide recognition. By targeting particular epitopes that are presented on self-HLA but are not strongly tolerated, the method enables localized immune responses against tumor-associated antigens while avoiding broad activation of self-reactive T cells that would be deleted during thymic development.
3Productivity
If only 600 CTL epitopes have been identified after two decades of research, then the field has made progress, but the number of functional epitopes remains far below the predicted 352,000 HLA ligands
Solution Approach 1:
The patent replaces traditional mechanical and manual epitope identification methods with a high-throughput system that combines computational prediction, synthetic peptide synthesis, and automated T cell screening. This substitution of manual approaches with integrated bioinformatics and immunological assays dramatically increases the productivity and quantity of identified epitopes, moving from 600 to potentially thousands of functional epitopes.
Solution Approach 2:
The patent applies universality by creating a multi-functional platform that can identify epitopes from various sources (viral, bacterial, and self-proteins), work with different HLA types, and serve multiple purposes including vaccine design, immunotherapy, and diagnostic marker identification. This universal system accelerates epitope discovery across diverse pathological contexts, increasing both the rate and quantity of identified functional epitopes.
Data Source
AI summary
The present invention relates to CTL peptide epitopes, high-throughput methods for their identification, and their uses. In particular, the present invention relates to peptide epitopes for cancer immunotherapy and Hepatitis C Virus vaccines. The present invention also relates to methods and systems for identifying antigen-specific CTLs.